Metacrine Stock Fundamentals
| MTCRDelisted Stock | USD 0.49 0.00 0.00% |
Metacrine fundamentals help investors to digest information that contributes to Metacrine's financial success or failures. It also enables traders to predict the movement of Metacrine Stock. The fundamental analysis module provides a way to measure Metacrine's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Metacrine stock.
Metacrine |
Metacrine Company Return On Asset Analysis
Metacrine's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Metacrine Return On Asset | -0.37 |
Most of Metacrine's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Metacrine is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Metacrine has a Return On Asset of -0.3686. This is 95.79% lower than that of the Healthcare sector and 98.44% lower than that of the Biotechnology industry. The return on asset for all United States stocks is 163.29% higher than that of the company.
Metacrine Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Metacrine's current stock value. Our valuation model uses many indicators to compare Metacrine value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Metacrine competition to find correlations between indicators driving Metacrine's intrinsic value. More Info.Metacrine is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Metacrine by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Metacrine Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Metacrine's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Metacrine could also be used in its relative valuation, which is a method of valuing Metacrine by comparing valuation metrics of similar companies.Metacrine is currently under evaluation in return on asset category among its peers.
Metacrine Fundamentals
| Return On Equity | -0.91 | |||
| Return On Asset | -0.37 | |||
| Current Valuation | (23.98 M) | |||
| Shares Outstanding | 42.57 M | |||
| Shares Owned By Insiders | 12.29 % | |||
| Shares Owned By Institutions | 35.96 % | |||
| Number Of Shares Shorted | 87.42 K | |||
| Price To Book | 0.40 X | |||
| Gross Profit | (45.47 M) | |||
| EBITDA | (60.71 M) | |||
| Net Income | (62.21 M) | |||
| Cash And Equivalents | 55.53 M | |||
| Cash Per Share | 1.30 X | |||
| Total Debt | 13.3 M | |||
| Debt To Equity | 0.33 % | |||
| Current Ratio | 22.29 X | |||
| Book Value Per Share | 0.87 X | |||
| Cash Flow From Operations | (47.16 M) | |||
| Short Ratio | 0.21 X | |||
| Earnings Per Share | (1.93) X | |||
| Target Price | 0.5 | |||
| Number Of Employees | 10 | |||
| Beta | -0.73 | |||
| Market Capitalization | 20.94 M | |||
| Total Asset | 79.99 M | |||
| Z Score | 0.6 | |||
| Net Asset | 79.99 M |
About Metacrine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Metacrine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Metacrine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Metacrine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Metacrine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.
Pair Trading with Metacrine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Metacrine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Metacrine will appreciate offsetting losses from the drop in the long position's value.Moving against Metacrine Stock
The ability to find closely correlated positions to Metacrine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Metacrine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Metacrine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Metacrine to buy it.
The correlation of Metacrine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Metacrine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Metacrine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Metacrine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Metacrine Stock
If you are still planning to invest in Metacrine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Metacrine's history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |